• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

iScience . Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

tetano

Editor, Senior Moderator
iScience


. 2023 Sep 22;26(10):108009.
doi: 10.1016/j.isci.2023.108009. eCollection 2023 Oct 20. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual

Denise Guerra[SUP] 1 2 [/SUP], Tim Beaumont[SUP] 1 2 [/SUP], Laura Radić[SUP] 1 2 [/SUP], Gius Kerster[SUP] 1 2 [/SUP], Karlijn van der Straten[SUP] 1 2 3 [/SUP], Meng Yuan[SUP] 4 [/SUP], Jonathan L Torres[SUP] 4 [/SUP], Wen-Hsin Lee[SUP] 4 [/SUP], Hejun Liu[SUP] 4 [/SUP], Meliawati Poniman[SUP] 1 2 [/SUP], Ilja Bontjer[SUP] 1 2 [/SUP], Judith A Burger[SUP] 1 2 [/SUP], Mathieu Claireaux[SUP] 1 2 [/SUP], Tom G Caniels[SUP] 1 2 [/SUP], Jonne L Snitselaar[SUP] 1 2 [/SUP], Tom P L Bijl[SUP] 1 2 [/SUP], Sabine Kruijer[SUP] 1 2 [/SUP], Gabriel Ozorowski[SUP] 4 [/SUP], David Gideonse[SUP] 5 [/SUP], Kwinten Sliepen[SUP] 1 2 [/SUP], Andrew B Ward[SUP] 4 [/SUP], Dirk Eggink[SUP] 1 2 5 [/SUP], Godelieve J de Bree[SUP] 2 3 [/SUP], Ian A Wilson[SUP] 4 6 [/SUP], Rogier W Sanders[SUP] 1 2 7 [/SUP], Marit J van Gils[SUP] 1 2 [/SUP]



Affiliations
Abstract

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has remained a medical threat due to the evolution of multiple variants that acquire resistance to vaccines and prior infection. Therefore, it is imperative to discover monoclonal antibodies (mAbs) that neutralize a broad range of SARS-CoV-2 variants. A stabilized spike glycoprotein was used to enrich antigen-specific B cells from an individual with a primary Gamma variant infection. Five mAbs selected from those B cells showed considerable neutralizing potency against multiple variants, with COVA309-35 being the most potent against the autologous virus, as well as Omicron BA.1 and BA.2, and COVA309-22 having binding and neutralization activity against Omicron BA.4/5, BQ.1.1, and XBB.1. When combining the COVA309 mAbs as cocktails or bispecific antibodies, the breadth and potency were improved. In addition, the mechanism of cross-neutralization of the COVA309 mAbs was elucidated by structural analysis. Altogether these data indicate that a Gamma-infected individual can develop broadly neutralizing antibodies.

Keywords: Immunology; Structural biology; Virology.

 
Back
Top Bottom